Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Angiogenesis has an essential role in tumor growth and metastasis, and blocking this
pathway has been a successfully utilized strategy in the clinical treatment of cancer …

Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …

The tyrosine kinase activity of epidermal growth factor receptors (EGFRs) plays critical roles
in cell proliferation, regeneration, tumorigenesis, and anticancer resistance. Non-small-cell …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …